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adateru Takayama, MD,† Junko Honye, MD,† Atsushi Hirayama, MD,†
atoshi Saito, MD,† Takahiko Suzuki, MD, PHD*
oyohashi and Tokyo, Japan
bjectives The aim of this study was to evaluate the effect of treatment with statins on the pro-
ression of coronary atherosclerotic plaques of a nonculprit vessel by serial volumetric virtual histol-
gy (VH) intravascular ultrasound (IVUS).
ackground Recent clinical trials have demonstrated a reduction of atherosclerotic plaque, yet
hether statin therapy affects the change in components of plaque remains unknown.
ethods This study was a nonrandomized and nonblinded design. Eighty patients with stable an-
ina pectoris were divided into either the ﬂuvastatin group (n  40) or the control group (n  40)
ccording to their total or low-density lipoprotein (LDL) cholesterol level. The volume of each
laque component (dense calcium, ﬁbrous tissue, ﬁbro-fatty, or necrotic core) was evaluated at
aseline and at 12-month follow-up.
esults The LDL cholesterol and high-sensitivity C-reactive protein (hsCRP) levels in the ﬂuvastatin
roup were signiﬁcantly decreased at time of follow-up. In VH IVUS ﬁndings, ﬁbro-fatty volume was
igniﬁcantly decreased (baseline 80.1  57.9 mm3 vs. follow-up 32.5  27.7 mm3, p  0.0001) and
brous tissue volume was increased (baseline 146.5  85.6 mm3 vs. follow-up 163.3  94.5 mm3,
 0.0001) in the ﬂuvastatin group. In the control group, the volumes of all plaque components
ithout ﬁbrous tissue were signiﬁcantly increased. Change in ﬁbro-fatty volume has a signiﬁcant
orrelation with a change in LDL cholesterol level (R  0.703, p  0.0001) and change in hsCRP
evel (R  0.357, p  0.006).
onclusions One-year lipid-lowering therapy by ﬂuvastatin showed signiﬁcant regression of plaque
olume and alterations in atherosclerotic plaque composition with a signiﬁcant reduction of ﬁbro-
atty volume. (J Am Coll Cardiol Intv 2009;2:689–96) © 2009 by the American College of
ardiology Foundation
rom the *Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan; and the †Department of Cardiology, Nihon
niversity Itabashi Hospital, Tokyo, Japan.anuscript received April 6, 2009, accepted April 19, 2009.
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Statin Therapy Evaluated by VH IVUS
690he effect of lipid-lowering therapy with statins in reducing
dverse cardiovascular events is well-recognized (1,2).
tatins have a wide range of biologic effects, including
eductions in the level of blood cholesterol and high-
ensitivity C-reactive protein (hsCRP), for stabilization of
therosclerotic plaque (1–6). Although it is possible that
tatins might affect plaque stabilization by modifying plaque
omposition, there are few data regarding changes for each
laque component of the atherosclerotic plaque (7,8). Vir-
ual histology (VH) (Volcano Corporation, Rancho Cor-
See page 697
ova, California) intravascular ultrasound (IVUS) uses spec-
ral analysis of the radiofrequency ultrasound backscatter
ignals, which allows for identifying 4 different types of
therosclerotic plaque components: fibrous, fibro-fatty,
ense calcium, and necrotic core (9). A direct comparison
etween in vivo VH IVUS and in vitro histopathology tissue
ample obtained by directional coronary atherectomy was
shown to have an 87% to 97%
accuracy for each plaque compo-
nent (10). The primary objective
of this study is to evaluate the
effect of fluvastatin on progres-
sion of coronary atherosclerotic
plaque evaluated by VH IVUS.
Methods
Study population and study design.
This study was a prospective and
multicenter study with nonran-
omized and nonblinded design. The inclusion criteria
onsisted of patients older than 30 years of age with
ymptomatic stable angina pectoris. All patients had signif-
cant 1- or 2-vessel diseases and were good candidates for
ercutaneous coronary intervention. Angiographic inclusion
riteria were: 1) target vessel for VH IVUS interrogation
ust not have undergone angioplasty or have more than
0% luminal narrowing throughout a target segment with a
inimum length of 30 mm; 2) target vessel for VH IVUS
nterrogation had mild-to-moderate vessel tortuosity and
alcification for safe and accurate examination; and 3) left
entricular ejection fraction 30%. Exclusion criteria were:
) significant stenotic lesions in all coronary vessels; 2)
nstable angina or myocardial infarction within the previous
weeks; 3) target vessel for VH IVUS interrogation had
esions with angiographically detected thrombus; 4) contra-
ndications to IVUS examination; 5) other concomitant
iseases or medical condition that could impact patient/
rocedural outcomes, such as history of bleeding diathesis,
bbreviations
nd Acronyms
EM  external elastic
embrane
sCRP  high-sensitivity
-reactive protein
VUS  intravascular
ltrasound
DL  low-density
ipoprotein
H  Virtual Histologytroke, or transient ischemic neurological attacks within the aast year or hypersensitivity to heparin, aspirin, ticlopidine,
r X-ray contrast media; 6) secondary causes of hyperlipid-
mia or uncontrolled triglyceride level above 500 mg/dl; and
) a positive pregnancy test. After diagnostic catheteriza-
ion, patients who met eligibility criteria for this study were
nvited to participate in this study. No patients were
eceiving lipid-lowering therapy before the enrollment of
his study. A control group was nonequivalent and designed
or comparison with the fluvastatin group in this study.
atients were divided into 2 groups according to their total
holesterol or low-density lipoprotein (LDL) cholesterol
evel at baseline. Patients with total cholesterol level above
20 mg/dl or LDL cholesterol level above 140 mg/dl were
reated by fluvastatin (60 mg/day). Usual care, such as a
ipid-lowering diet, was administrated for patients with total
holesterol and LDL cholesterol levels 220 mg/dl and
140 mg/dl, respectively. Follow-up visits were scheduled
very month. Major adverse cardiac events, including death
ttributed to cardiac causes and myocardial infarction or
ew angina related to the target vessel for VH IVUS
nterrogation or percutaneous coronary intervention, were
eported. Angiographic and VH IVUS follow-up was
cheduled for the target vessel after 1 year. Informed
onsent was obtained from patients and their relatives in all
ases. The institutional ethics committee of the 2 centers
pproved the study.
ata acquisition and medication. All patients were given
spirin (100 mg/day) and ticlopidine (200 mg/day) or
lopidogrel (75 mg/day) for at least 1 week before the
rocedure. During the procedure, heparin was given as a
olus of 150 U/kg with additional boluses to 2,000 U/h.
fter successful percutaneous coronary intervention, IVUS
maging was performed for the target vessel for VH IVUS
nalysis after administration of 200 g of nitroglycerin. For
he IVUS procedure, a 20-MHz, 3.2-F, phased-array IVUS
atheter (Eagle Eye, Volcano Corporation) was used. After
lacing the IVUS catheter at a point that was distant at least
0 mm from the coronary ostium, the catheter was pulled
ack to the coronary ostium with a motorized pull-back
ystem at 0.5 cm/s. During pullback, gray-scale IVUS was
ecorded and raw radiofrequency data was captured at the
op of the R-wave for reconstruction of the color-coded map
y a VH IVUS data recorder (Volcano Corporation). The
ray-scale IVUS movie and captured radiofrequency data
ere written on a recordable compact disc and recordable
igital video disc, respectively.
ray-scale and VH IVUS analyses. Before IVUS analysis,
aseline and follow-up IVUS images were reviewed side by
ide on a display, and the distal end of the target segment
as determined by the presence of a reproducible index side
ranch. Manual contour detection of both the lumen and
he media-adventitia interface was performed by an experi-
nced analyst who was blinded to baseline clinical and
ngiographic lesion characteristics. Intra-observer analysis
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691n random samples of 40 vessels was performed by the
xperienced analyst at least 2 weeks apart. Intra-observer
ifferences in measurements of external elastic membrane
EEM) volume and lumen volume were 3.2 2.0% and 3.7
2.2%, respectively. The EEM volume and lumen volume
ere calculated, and the difference between the 2 values was
efined as plaque plus media volume. Atherosclerotic cor-
nary plaques between the lumen and media-adventitia
ontours were characterized automatically with the use of
ustom-built software (IVUSLab software, Volcano Corpo-
ation) that uses classification trees based on mathematical
utoregressive spectral analysis of IVUS backscattered data,
s described previously (11). Fibrous tissue was marked in
reen, fibro-fatty in yellow, dense calcium in white, and
ecrotic core in red on the VH IVUS image. The absolute
alue of each plaque component was also calculated auto-
atically by the software.
tatistical analysis. Continuous data are represented as
ean  SD. Categorical data were expressed as numbers or
requencies of occurrence. Comparison of continuous vari-
bles between baseline and follow-up in each group was
erformed by 2-tailed paired Student t test for normally
istributed variables and by Aspin-Welch’s t test for vari-
bles with heterogeneity of variance. The chi-square test or
isher exact test for sparse data was used for comparing
requency of occurrence. Correlation changes in each plaque
omponent volume with changes in LDL cholesterol and
sCRP were analyzed by liner regression analysis. The
PSS version 11.0 software (SPSS, Inc., Chicago, Illinois)
as used for data analysis. A p value of 0.05 was
onsidered to indicate statistical significance.
esults
atient and analyzed vessel characteristics. From Septem-
er 2004 to December 2005, 85 patients met all inclusion
nd exclusion criteria, and informed consent was obtained.
f those patients, 5 were not included in this study due to
rtifacts or pull-back shorter than the pre-specified mini-
um length of 30 mm. During the study period, 1 patient
n the control group was withdrawn due to the occurrence of
ung cancer; however, no patient was withdrawn due to
rug-related side effects such as rash, arthralgia, increase in
reatinine, or deep venous thrombosis. Thus, both baseline
nd follow-up IVUS examinations were performed for 40
atients with 40 vessels in the fluvastatin group and 39
atients with 39 vessels in the control group. Baseline
haracteristics are summarized in Table 1. All patient and
nalyzed vessel characteristics did not vary between the 2
roups.
aboratory outcomes. Baseline and follow-up laboratory
ata are summarized in Table 2. At baseline, total choles-
erol, LDL cholesterol, triglyceride, and hsCRP levels in the
uvastatin group were significantly higher than those of the aontrol group. However, at 1-year follow-up, total choles-
erol, triglyceride, LDL cholesterol, apolipoprotein B, and
sCRP levels of the fluvastatin group were significantly
ower than those of the control group. Especially, LDL
holesterol and hsCRP levels were significantly decreased by
1.8% and 48.9% in the fluvastatin group during the
ollow-up period compared with increases of 1.5% (p 
.0001) and 0.2%, respectively, in the control group (p 
.0001).
ray-scale IVUS measurements. Table 3 shows baseline and
-year follow-up results of volumetric gray-scale IVUS
nalyses. In the fluvastatin group, EEM and plaque plus
edia volumes were significantly decreased, but there was
o change in lumen volume compared with baseline. In
ontrast, EEM, lumen, and plaque plus media volumes were
ot changed in the control group. Changes in EEM and
laque plus media volumes were also significantly smaller in
he fluvastatin group compared with the control group.
H IVUS measurements. Volumetric VH IVUS analysis is
ummarized in Table 4. At baseline, fibro-fatty volume in
he fluvastatin group was significantly higher than that in
he control group. However, during the 1-year follow-up
eriod, volumes of all plaque components without fibrous
issue in the control group were significantly increased.
onversely, the fibro-fatty volume was significantly de-
reased and the fibrous tissue volume was significantly
ncreased in the fluvastatin group. However, necrotic core
Table 1. Baseline Patients and Lesion Characteristics
Fluvastatin Control p Value
n 40 40
Male 32 (80) 31 (78) 0.99
Age, yrs 63  10 62  12 0.57
Prior PCI 8 (20) 6 (15) 0.77
Hypertension 20 (50) 18 (45) 0.81
Diabetes 11 (28) 10 (25) 0.99
Current smoker 19 (48) 20 (50) 0.99
Use of ACE inhibitor 17 (43) 15 (38) 0.76
Use of AT1 antagonist 16 (40) 14 (35) 0.31
Nature of coronary artery disease
Single-vessel 32 (80) 31 (78) 0.82
Multivessel 8 (20) 9 (22) 0.82
Analyzed vessel
LAD 13 (33) 8 (21) 0.31
LCX 13 (33) 16 (41) 0.49
RCA 14 (34) 15 (38) 0.82
Values are n (%) or mean  SD. Fisher exact test was used for categorical data, and unpaired
Student t test was used for continuous data between fluvastatin and control groups. Values of
p 0.05 were considered statistically significant.
ACE  angiotensin-converting enzyme; AT1  angiotensin receptor 1; LAD  left anterior
descending artery; LCX  left circumflex artery; PCI  percutaneous coronary intervention;
RCA right coronary artery.nd dense calcium volumes remained unchanged during the
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692ollow-up period. Therefore, changes in volumes of all
laque components, excluding fibrous tissue in the fluva-
tatin group, were significantly smaller than those in the
ontrol group. Figure 1 shows the correlation change in
olume of each plaque component with change in LDL
holesterol level. Change in fibro-fatty volume has a signif-
cant correlation with a change in LDL cholesterol level
R  0.703, p  0.0001); however, changes in volumes of
he other plaque components are not correlated with a
hange in LDL cholesterol level (fibrous tissue: R  0.233,
 0.09; necrotic core: R  0.199, p  0.13; dense
alcium: R  0.056, p  0.68). The correlation change in
olume of each plaque component with change in hsCRP
Table 2. Blood Parameters at Baseline and Follow-Up
Baseline
Fluvastatin Control
n 40 40
Total cholesterol, mg/dl 239.1 32.8 199.5 22.8
Triglyceride, mg/dl 200.6 125.4 122.8 50.1
HDL cholesterol, mg/dl 52.7 12.4 54.3 17.8
LDL cholesterol, mg/dl 144.9 31.5 122.3 18.9
Reduction in LDL cholesterol, % — —
Apolipoprotein A1, mg/dl 114.3 20.0 110.1 22.6
Apolipoprotein B, mg/dl 97.9 20.1 91.4 19.6
Apolipoprotein E, mg/dl 4.6 2.3 4.5 0.7
hsCRP, mg/l 2.05 2.20 1.19 1.03
Reduction in hsCRP, % — —
Values are mean SD when appropriate. Paired Student t test or Aspin-Welch’s t test was used for
significant. *p 0.0001 compared with baseline; †p 0.01 compared with baseline.
HDL high-density lipoprotein; hsCRP high-sensitivity C-reactive protein; LDL low-density
Table 3. Baseline and Follow-Up Gray-Scale Intravascular
Ultrasound Results
Fluvastatin Control p Value
n 40 39
Average length 52.9 23.3 52.0 23.6 0.88
External elastic membrane volume
Baseline, mm3 813.9 398.5 877.6 458.3 0.57
Follow-up, mm3 780.5 390.0* 884.1 422.2 0.2
Change in vessel volume, mm3 33.4 50.1 8.1 11.0 0.007
Lumen volume
Baseline, mm3 373.7 188.4 444.7 233.5 0.21
Follow-up, mm3 374.4 194.5 439.3 204.4 0.41
Change in lumen volume, mm3 0.7 34.7 5.4 4.8 0.37
Plaque plus media volume
Baseline, mm3 440.2 220.3 432.9 247.5 0.9
Follow-up, mm3 403.8 209.4† 443.7 258.5 0.1
Change in plaque plus media
volume, mm3
36.4 42.6 11.2 7.6 0.0001
Values aremean SDwhenappropriate. Paired Student t test or Aspin-Welch’s t testwasused for
continuous data between fluvastatin and control groups. Values of p  0.05 were consideredstatistically significant. *p 0.01 compared with baseline; †p 0.0001 compared with baseline.evel is summarized in Figure 2. As with the correlation
hange in LDL cholesterol level, change in fibro-fatty
olume was significantly correlated with change in hsCRP
evel (R  0.357, p  0.006); however, there were no
orrelations between changes in volumes of the other plaque
omponents and change in hsCRP level (fibrous tissue: R
.032, p  0.81; necrotic core: R  0.198, p  0.14; dense
alcium: R  0.107, p  0.43). Figure 3 shows a represen-
Follow-Up
p Value Fluvastatin Control p Value
40 39
0.0001 179.2 29.1* 205.0 26.9 0.0001
0.003 111.4 49.4† 132.2 56.6 0.02
0.67 53.9 12.3 54.0 13.9 0.99
0.002 98.1 12.7† 121.0 21.2 0.004
— 31.8 25.7 1.5 1.8 0.0001
0.51 123.7 21.6 122.3 24.5 0.84
0.29 71.5 15.1* 93.5 27.1 0.003
0.1 3.7 1.6 3.6 1.1 0.87
0.01 1.07 0.27† 1.23 1.15 0.004
— 48.9 20.1 0.2 2.1 0.0001
ous data between fluvastatin and control groups. Values of p 0.05 were considered statistically
tein.
Table 4. Baseline and Follow-Up Gray-Scale Virtual Histology
Intravascular Ultrasound Results
Fluvastatin Control p Value
n 40 39
Fibrous tissue volume
Baseline, mm3 146.5 85.6 142.9 113.3 0.89
Follow-up, mm3 163.3 94.5* 146.3 102.6 0.21
Change in ﬁbrous tissue
volume, mm3
16.8 15.0 4.4 5.3 0.03
Fibro-fatty volume
Baseline, mm3 80.1 57.9 50.7 32.9 0.01
Follow-up, mm3 32.5 27.7* 73.3 46.9† 0.005
Change in ﬁbro-fatty
volume, mm3
48.4 47.2 23.6 16.7 0.0001
Necrotic core volume
Baseline, mm3 21.4 24.9 22.1 17.4 0.9
Follow-up, mm3 18.8 16.8 31.0 22.4† 0.02
Change in necrotic core
volume, mm3
2.6 10.3 8.9 17.7 0.004
Dense calcium volume
Baseline, mm3 9.4 9.9 13.7 12.7 0.15
Follow-up, mm3 9.9 9.6 20.3 19.2† 0.01
Change in dense calcium
volume, mm3
0.4 3.4 6.5 14.5 0.03
Values aremean SDwhenappropriate. Paired Student t test or Aspin-Welch’s t testwasused for
continuous data between fluvastatin and control groups. Values of p  0.05 were consideredcontinustatistically significant. *p 0.0001 compared with baseline; †p 0.01 compared with baseline.
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693ative vessel from each group. Baseline and 1-year follow-up
ray-scale and VH IVUS images are presented side by side.
n the fluvastatin group, volumetric analyses showed a
arked increase of fibrous tissue volume (from 124.59 mm3
o 151.79 mm3) and reduction of fibro-fatty volumes (from
2.53 mm3 to 31.49 mm3) (Fig. 3A). However, in the
ontrol group, volumes of all plaque components without
brous tissue increased during the follow-up period (Fig. 3B).
ajor adverse cardiac events. Major adverse cardiac events
ccurred in 4 fluvastatin and 11 control patients (Table 5).
iscussion
his is the first clinical study to assess the effect of statin for
laque components by serial volumetric VH IVUS study.
he main finding of this study was that 1-year lipid-
owering therapy by fluvastatin showed a plaque regression
y a significant reduction of fibro-fatty volume with a shift
o a more fibrotic lesion morphology in hyperlipidemic
Figure 1. Correlation Between Change in LDL Cholesterol Level and Chang
Change in ﬁbro-fatty volume was signiﬁcantly correlated with a change in low
no signiﬁcant correlation between changes in volume of the other plaque comatients. In addition, the degree of reduction in fibro-fatty Iolume was positively correlated with the changes in LDL
holesterol and hsCRP levels.
In this study, the reduction of EEM volume with a
ignificant plaque reduction was shown in the fluvastatin
roup from gray-scale IVUS findings. However, the regres-
ion or progression of each plaque component was unknown
rom gray-scale IVUS findings. In native coronary lesions of
onhuman primates, histological studies have demonstrated
ipid depletion and fibrosis during lipid-lowering therapy
12–14). A previous study using gray-scale IVUS tried to
valuate the change in plaque components during lipid-
owering therapy (15). In that study, a percent of hyper-
chogenic area, determined with a computer-aided gray-
cale value analysis, was significantly increased, and the
ypoechogenic area remained unchanged. However, iden-
ification of atherosclerotic plaque components by densito-
etric category of gray-scale IVUS is limited due to
rocessing of the raw radiofrequency data (16–18). The VH
olume of Each Plaque Component
ty lipoprotein (LDL) cholesterol level as shown in B (p  0.0001). There was
nts and change in LDL cholesterol level as shown in A, C, and D.e in V
-densiVUS uses spectral analysis of the radiofrequency ultrasound
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694ackscatter signals, which allows for identifying 4 different
ypes of atherosclerotic plaque components: fibrous, fibro-
atty, dense calcium, and necrotic core. In the VH IVUS
ndings of this study, a significant reduction of fibro-fatty
nd increase of fibrous tissue by lipid-lowering therapy were
bserved. In contrast, fibro-fatty volume was significantly
ncreased in the control group although total plaque plus
edia volume was not changed. In addition, change in
bro-fatty volume had a significant positive correlation with
change in LDL cholesterol level (R  0.703, p  0.0001).
ibro-fatty is defined as fibrous tissue with significant lipid
nterspersed in collagen in VH IVUS findings (9,10). The
nterspersed lipids in fibro-fatty tissue might be regressed from
he atherosclerotic intima with reducing continued influx;
ence, an accumulation of interstitial collagen in fibrous tissue
ight be significantly increased by lipid-lowering therapy (14).
hus, the fibro-fatty volume might possibly be a reversible step
f atherosclerosis. However, the volume of necrotic core
emained unchanged during follow-up period in the fluvastatin
roup, although that of the control group was significantly
Figure 2. Correlation Between Change in hsCRP Level and Change in Volum
Change in ﬁbro-fatty volume was signiﬁcantly correlated with a change in hig
no signiﬁcant correlation between changes in volume of the other plaque comncreased. In addition, the change in necrotic core volume had io correlation with the change in LDL-cholesterol level (R 
.199, p  0.13). In histopathological findings, necrotic cores
ave macrophage infiltrations, which are undergoing apoptotic
ell death, and the matrix is no longer distinct. Thus, necrotic
ore might be an irreversible step of atherosclerosis (19). The
esults of the study indicate that statins might prevent the
rogression of atherosclerosis due to reduced fibro-fatty vol-
me and retard the upward trend of necrotic core volume.
Additionally, statins have been recognized as having
eneficial effects on vascular inflammation, lipid oxidation,
nd endothelial function, the so-called pleiotropic effects, as
ell as lipid-lowering functionality. A few previous studies
howed that hsCRP, a marker of systemic inflammation,
as synthesized locally in atherosclerotic plaque (20,21) and
n higher amounts in unstable compared with stable plaque
22,23). In this study, change in fibro-fatty volume had a
ignificant positive correlation with change in hsCRP level
R  0.357, p  0.006). These results were supported by a
revious report that regression of local atherosclerosis was
ignificantly associated with attenuating the endothelial
Each Plaque Component
itivity C-reactive protein (hsCRP) level as shown in B (p  0.006). There was
nts and change in hsCRP level as shown in A, C, and D.e of
h-sensnflammatory response and macrophage-to-foam cell trans-
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695ormation (24). However, although statin therapy reduced
sCRP level significantly, necrotic core volume—which
ight be an irreversible step of atherosclerosis—did not
hange, and there was no correlation change in necrotic core
olume with change in hsCRP level (R  0.198, p  0.14)
n this study. A previous study that evaluated stable and
nstable coronary plaque by VH IVUS showed that high
alues of serum hsCRP level and necrotic core ratio were
ignificantly associated with the degree of inflammation in
he process of plaque instability (25). Thus, statin therapy
an not reverse fibroatheroma to the previous stage of
therosclerosis. Even so, statin therapy could prevent plaque
Figure 3. Baseline and 1-Year Follow-Up Gray-Scale and Virtual Histology In
(A) A representative vessel from the ﬂuvastatin group. Volumetric analyses sho
umes. (B) A representative vessel from the control group. Volumes of all plaqu
Table 5. Major Adverse Cardiac Events
Fluvastatin Control p Value
n 40 39
Any events, n (%) 4 (10) 11 (28) 0.09
Stable angina, n (%) 1 (3) 5 (13) —
Unstable angina, n (%) 0 0 —
Myocardial infarction, n (%) 0 1 (3) —
Reintervention, n (%) 3 (8) 5 (13) —
New intervention, n (%) 0 0 —
CABG, n (%) 0 0 —
Death, n (%) 0 0 —
Fisher exact test was used for categorical data, and paired Student t test or Aspin-Welch’s t test
was used for was used for continuous data between fluvastatin and control groups. Values of p
0.05 were considered statistically significant.aCABG coronary artery bypass graft.upture by reduction of macrophage accumulations and
atrix metalloproteinase activity (26). A previous study
sing optical coherence tomography showed that the inci-
ence of plaque rupture was significantly decreased and the
hickness of fibrous cap tended to increase with statin
herapy (27). These might explain the mechanisms to
revent plaque rupture and stabilize fibroatheroma includ-
ng a large necrotic core.
tudy limitations. First, this study population consisted of
nly 80 patients from 2 centers. A study of larger patient
opulations from various centers is warranted to confirm
hese data. Second, although averages of analyzed length in
oth groups were over 50 mm, those were only small
egments of the entire coronary artery. Third, the present
H IVUS technology is unable to differentiate thrombus
rom other plaque components. The subjects of this study
ere stable angina pectoris patients, and lesions with an-
iographically detected thrombus were excluded; however,
his algorithm relies on the placement of 2 borders—
amely, the luminal border and the media-adventitia bor-
er—so that small thrombus within these 2 borders might
ead to incorrect tissue characterization. Fourth, fluvastatin
s not a strong statin, because follow-up LDL cholesterol
evel in the fluvastatin group (98.1 mg/dl) was higher than
hat in previous reports (3–5). However, fluvastatin might
e delivered to the vessel wall in an amount sufficient for its
herapeutic effect and have a direct action to stabilize
scular Ultrasound Images Are Presented Side by Side
he marked increase of ﬁbrous tissue volume and reduction of ﬁbro-fatty vol-
ponents without ﬁbrous tissue increased during the follow-up period.trava
wed ttherosclerosis (28). Fifth, the presence of many drivers,
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696ncluding blood pressure, smoking, diabetes mellitus, or
nknown genetic factors, might impact the results of this
tudy. Finally, this study was nonrandomized. Those cases
ith either total cholesterol level more than 220 mg/dl or
DL cholesterol level more than 140 mg/dl were treated for
yperlipidemia, because of ethical considerations.
onclusions
tatin therapies designed to reduce lipid profiles, and
nflammation might change the plaque morphology and
revent progression of atherosclerosis. In addition, the
hange of plaque composition might be associated with
linical stabilization from the trend to fewer clinical events.
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